Not available
Quote | Innoviva Inc. (NASDAQ:INVA)
Last: | $15.16 |
---|---|
Change Percent: | -0.07% |
Open: | $15.18 |
Close: | $15.16 |
High: | $15.295 |
Low: | $15.04 |
Volume: | 424,950 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Innoviva Inc. (NASDAQ:INVA)
Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific S...
2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...
Message Board Posts | Innoviva Inc. (NASDAQ:INVA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $INVA News Article - Innoviva Completes Acquisition of Entasis Therapeutics | whytestocks | investorshangout | 07/11/2022 3:30:55 PM |
whytestocks: $INVA News Article - Innoviva to Acquire La Jolla Pharmaceutical Company | whytestocks | investorshangout | 07/11/2022 3:17:01 PM |
whytestocks: $INVA News Article - Watch for Continued Gains in Shares of Innoviva Inc. (INVA) | whytestocks | investorshangout | 02/14/2022 7:15:48 PM |
whytestocks: $INVA News Article - Innoviva Announces Strategic Repurchase of GSK's Equity Stake | whytestocks | investorshangout | 05/20/2021 4:25:49 PM |
whytestocks: $INVA News Article - 2 Incredibly Cheap Biotech Stocks | whytestocks | investorshangout | 12/23/2019 6:45:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific S...
2024-04-12 13:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...